Timing of Anticoagulation for Posterior Circulation Infarcts with Possible Paroxysmal AF

Introduction to Anticoagulation Timing

The American Heart Association recommends initiating direct oral anticoagulant (DOAC) therapy within 3-6 days post-stroke for mild-to-moderate strokes, and delaying until 12-14 days for severe strokes, avoiding parenteral anticoagulation within the first 48 hours 1

The optimal timing of anticoagulation has not been definitively established by randomized trials, but current expert consensus provides a structured approach based on stroke severity, as recommended by the European Society of Cardiology 1, 2

For transient ischemic attack (TIA) or very mild stroke, the European Stroke Organisation recommends initiating DOAC on day 1 or same day after imaging excludes hemorrhage 1
For mild stroke (NIHSS ≤5), the American College of Cardiology recommends starting DOAC at day 3 post-event 1
For moderate stroke (NIHSS 6-15), the European Society of Cardiology recommends beginning DOAC at day 6 post-event 1
For severe stroke (NIHSS >15) or large infarct, the Canadian Stroke Best Practice guidelines recommend delaying DOAC initiation to 12-14 days to minimize hemorrhagic transformation risk 1, 3, 2

Anticoagulation should generally be initiated within 2 weeks of acute ischemic stroke, as recommended by the Canadian Stroke Best Practice guidelines, to balance recurrent stroke risk against hemorrhagic transformation 1, 2

The American College of Chest Physicians explicitly states that parenteral anticoagulation (heparin, LMWH, or heparinoids) should not be used within 48 hours of stroke onset, as it increases symptomatic intracranial hemorrhage without net benefit 2

Before starting anticoagulation, cerebral imaging (CT or MRI) should be obtained to exclude hemorrhage, as recommended by the European Heart Journal 3

Direct oral anticoagulants (DOACs) are strongly preferred over warfarin for post-stroke anticoagulation in AF, as recommended by the International Journal of Stroke, due to lower intracranial hemorrhage risk and more predictable pharmacokinetics 1, 2

Beyond stroke severity, specific factors such as large infarct size (>1/3 MCA territory equivalent) and uncontrolled hypertension mandate more conservative timing, as recommended by the European Heart Journal and the International Journal of Stroke 1, 3, 2

Once anticoagulation begins, medication adherence should be assessed at each follow-up visit, and renal function (creatinine clearance) should be monitored at least annually for DOAC patients, as recommended by the International Journal of Stroke 1